Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP7 | P09237 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | MMP12 | P39900 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 4/20 | 0.48 |
| ▸ | CPA2 | P48052 | 3/20 | 0.48 |
| ▸ | CPA4 | Q9UI42 | 3/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.48 |
| ▸ | CPB1 | P15086 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 3/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2633304 | 0.87 | REN (0.43) | GNPATCPA1CPA2CPA4ACE2 | |
| SCHEMBL14232442 | 0.87 | REN (0.43) | GNPATCPA1CPA2CPA4ACE2 | |
| SCHEMBL10105751 | 0.85 | CPA1 (0.47) | MMP2MMP12MMP13CPA1CPA2 | |
| SCHEMBL2633287 | 0.85 | PSMB5 (0.52) | — | |
| SCHEMBL10105787 | 0.84 | PSMB5 (0.46) | — | |
| SCHEMBL30777486 | 0.83 | MME (0.65) | GNPATMMP2MMP7MMP9MMP12 | |
| SCHEMBL15692334 | 0.83 | MME (0.65) | GNPATMMP2MMP7MMP9MMP12 | |
| SCHEMBL19546018 | 0.82 | GNPAT (0.43) | GNPATCPA1CPA2CPA4ACE2 | |
| SCHEMBL17948648 | 0.81 | CPA1 (0.63) | GNPATMMP2MMP7MMP9MMP12 | |
| SCHEMBL2632716 | 0.80 | CPA1 (0.49) | MMP2MMP12MMP13CPA1CPA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| WO-2005111008-A2 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, CPN1 | GNPAT 4257/4885MMP2 270/4885MMP7 985/4885 |
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | GNPAT 3488/4885MMP2 211/4885MMP7 624/4885 |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | GNPAT 3488/4885MMP2 211/4885MMP7 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.